Leonaviciute Gintare, Adamovic Nada Trivic, Lam Hung Thanh, Rohrer Julia, Partenhauser Alexandra, Bernkop-Schnürch Andreas
Department of Pharmaceutical Technology, Institute of Pharmacy, Center for Chemistry and Biomedicine, Leopold - Franzens University Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Department of Pharmaceutical Technology, Institute of Pharmacy, Center for Chemistry and Biomedicine, Leopold - Franzens University Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Eur J Pharm Biopharm. 2017 Mar;112:51-57. doi: 10.1016/j.ejpb.2016.11.019. Epub 2016 Nov 19.
The objective of this study was to provide a proof-of-concept that self-emulsifying drug delivery systems can be made mucoadhesive by the incorporation of hydrophobic mucoadhesive polymers.
In order to obtain such a hydrophobic mucoadhesive polymer, Eudragit® S100 was thiolated by covalent attachment of cysteamine. After determination of the thiol group content, in vitro mucoadhesion studies (rotating cylinder and rheological measurements) were performed. Then, synthesized conjugate was incorporated into self-emulsifying drug delivery systems (SEDDS) and their toxic potential as well as that of unmodified and thiolated Eudragit® S100 was examined on Caco-2 cell line. Lastly, the mucoadhesiveness of developed SEDDS on porcine intestinal mucosa was determined.
Generated thiolated Eudragit® S100 displaying 235±14μmol of free thiol groups and 878±101μmol of disulfide bonds per gram polymer showed a great improvement in both: dynamic viscosity with mucus and adhesion time on mucosal tissue compared to the unmodified polymer. Resazurin assay revealed that unmodified and thiolated polymers and also SEDDS dispersions were non-toxic over Caco-2 cells. Furthermore, the incorporation of 1.5% (w/w) of such thiomer into SEDDS led to remarkably improved mucoadhesiveness. Blank SEDDS were completely removed from the mucosa within 15min, whereas >60% of SEDDS containing thiolated Eudragit® S100 were still attached to it.
These results provide evidence that SEDDS can be made mucoadhesive by the incorporation of hydrophobic mucoadhesive polymers.
本研究的目的是提供一个概念验证,即通过加入疏水性粘膜粘附聚合物可以使自乳化药物递送系统具有粘膜粘附性。
为了获得这种疏水性粘膜粘附聚合物,通过半胱胺的共价连接对Eudragit® S100进行硫醇化。在测定硫醇基团含量后,进行了体外粘膜粘附研究(旋转圆筒法和流变学测量)。然后,将合成的共轭物加入自乳化药物递送系统(SEDDS)中,并在Caco-2细胞系上检测其毒性潜力以及未修饰和硫醇化的Eudragit® S100的毒性潜力。最后,测定了所开发的SEDDS在猪肠粘膜上的粘膜粘附性。
每克聚合物产生的硫醇化Eudragit® S100显示出235±14μmol的游离硫醇基团和878±101μmol的二硫键,与未修饰的聚合物相比,其在与粘液的动态粘度和在粘膜组织上的粘附时间方面均有显著改善。刃天青试验表明,未修饰和硫醇化的聚合物以及SEDDS分散体对Caco-2细胞无毒。此外,将1.5%(w/w)的这种硫醇聚合物加入SEDDS中可显著提高粘膜粘附性。空白SEDDS在15分钟内从粘膜上完全清除,而含有硫醇化Eudragit® S100的SEDDS中有>60%仍附着在粘膜上。
这些结果证明,通过加入疏水性粘膜粘附聚合物可以使SEDDS具有粘膜粘附性。